检索
AI 对话
AI 辅写
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

15517 Eczema Area and Severity Index 90 (EASI-90) responder rates with abrocitinib and relationship with quality of life (QoL) and itch in patients with moderate to severe atopic dermatitis: Results from a randomized phase 3 clinical trial

Gil Yosipovitch,Thomas Bieber,Linda Stein Gold,Shawn Kwatra,Svitlana Tatulych,Chudy Nduaka,Michael C. Cameron,David Williams,Pinaki Biswas,Hernan Valdez

Journal of The American Academy of Dermatology（2020）

引用 4|浏览1
暂无评分
摘要
Introduction: Abrocitinib is an oral Janus kinase 1 inhibitor under investigation for the treatment of moderate to severe AD.
更多
查看译文
关键词
severe atopic dermatitis,atopic dermatitis,eczema area,severity index
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要